Global Intravenous (IV) Iron Drugs Market 2018-2022 – Vifor Pharma AG, Sanofi, AMAG Pharmaceuticals, Daiichi Sankyo Profiled

Global Intravenous (IV) Iron Drugs Market: Size, Trends and Forecasts (2018-2022)“, provides an in depth analysis of the global intravenous (IV) iron drugs market by value, by product, by type, by region, etc. The report also provides a regional analysis of the intravenous (IV) iron drugs market, including the following regions: The US and Europe. The report also provides a detailed analysis of the US intravenous (IV) iron drugs market by value, by products and by indication.

The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global intravenous (IV) iron drugs market has also been forecasted for the period 2018-2022, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

The global intravenous (IV) iron drugs market is highly fragmented with many intravenous (IV) iron drugs market players operating worldwide. Some intravenous (IV) iron drugs market players operating on a local level while other players operating on a regional and global level. The manufacturers of intravenous (IV) iron drugs market produce intravenous iron drugs for different indications, with different iron content and in different doses.

However, the competition in the global intravenous (IV) iron drugs market is dominated by few intravenous iron drugs manufacturers. Further, key players of the intravenous (IV) iron drugs market are Vifor Pharma AG, Sanofi, AMAG Pharmaceuticals, Inc. and Daiichi Sankyo Co., Ltd. are also profiled with their financial information and respective business strategies.


Country Coverage

The US

Company Coverage

Vifor Pharma AG
AMAG Pharmaceuticals, Inc.
Daiichi Sankyo Co., Ltd.

Executive Summary

Iron is one of the most essential mineral found in the human body. About 70% of the iron in the body is present in the red blood cells, called hemoglobin. Hemoglobin is required in the body to transport oxygen throughout the body via the blood. Deficiency of iron in the human body leads to severe health problems, which are associated with morbidity and mortality. To maintain the required level of iron in the body, iron supplements are given to the patients.

Iron supplements can be given in two forms: oral iron drugs and intravenous (IV) iron drugs. Oral iron drugs can be in the form of capsules, tablets or liquid drops. Intravenous iron drugs are given by injecting iron directly inside the body with a needle through a vein.

Intravenous iron drugs are favorably more preferred over oral iron drugs due to less side effects profile (oral iron drugs are not tolerable for many patients due to the poor gastrointestinal side effect); greater efficacy & better absorption (intravenous iron drugs are transported to the bone marrow through blood without need for absorption in the gut) and ensuring more efficient treatment (intravenous therapy allows larger dose of treatment over a short period of time).

Intravenous iron drugs have a long history with continuously evolving new generation intravenous iron drugs. The intravenous (IV) iron drugs market can be segmented on the basis of product, type and indication.

The global intravenous (IV) iron drugs market has increased at a significant CAGR during the years 2013-2017 and projections are made that the market would rise in the next four years i.e. 2018-2022 tremendously. The intravenous (IV) iron drugs market is expected to increase due to aging population, growing chronic diseases, escalating diabetic population, rising number of patients with chronic kidney disease, surge in the number of people with cancer, etc. Yet the market faces some challenges such as shift from Erythropoietin Stimulating Agents (ESAs) to HIF inhibitors, side effects associated with the use of intravenous iron drugs, etc.

Buy this report via Credit Card/Paypal or Wire Transfer:

Contact Us:
Ritesh Tiwari, Director
USA: +1-800-416-3124

Follow us on Social Media:

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: *Industry Press Release is a part of Research By Markets.